Nektar Therapeutics provided earnings guidance for the year 2023. The company's GAAP revenue for full year 2023 is expected to be between $80 million and $90 million. This revenue includes $65 million to $70 million in noncash royalties and $15 million to $20 million in product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +2.94% | -4.37% | +209.73% |
09/05 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
09/05 | Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+209.73% | 321M | |
+37.74% | 723B | |
+32.22% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.60% | 244B | |
+9.77% | 208B | |
-5.15% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Earnings Guidance for the Year 2023